

jc

JCWSCS 05 OCT 2004

10/05/2004 10:08 FAX 512 536 4598

FULBRIGHT @ JAWORSKI

001/007

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701-3271

WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: October 5, 2004

MATTER NUMBER:

10311924

GOUD:038US

RECIPIENT:	FAX NO.:	PHONE NO.:
Patent and Trademark Office	703/746-9195	703/308-1202

FROM: Martha A. Robinson

USER ID: MR10031

FLOOR: 20

PHONE: (512) 536-5616

FAX: (512) 536-4598

RE: REQUEST FOR CORRECTED FILING RECEIPT

NUMBER OF PAGES WITH COVER PAGE: 6 Originals Will Not Follow

Message:

U.S. Application No. 10/671,340 entitled "MODIFIED GLP-1 PEPTIDES WITH INCREASED BIOLOGICAL POTENCY" by Denis Gravel et al.

Thank you for your attention to this matter.

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
MARTHA ROBINSON AT 512/536-5616 AS SOON AS POSSIBLE.**

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:
Denis Gravel et al.

Serial No.: 10/671,340

Filed: September 25 2003

For: MODIFIED GLP-1 PEPTIDES WITH
INCREASED BIOLOGICAL POTENCY

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: GOUD:038US

CERTIFICATE OF FACSIMILE TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being
transmitted to: Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, facsimile number (703) 746-
9195 on the date below:

October 5, 2004
Date

Michael R. Krawczanek
Michael R. Krawczanek

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


A corrected filing receipt is requested in view of the error that appears in the original.
For the convenience of the Patent and Trademark Office, attached is a photocopy of the original
receipt on which the error has been noted.

There is an error in name of the Assignee under Assignment for Published Application.
Please delete "THERATECHNOLOGIES INC." and add --THERATECHNOLOGIES INC.--
In support of this requested correction, Applicants attach a copy of the assignment.

No fee is believed to be due in connection with the filing of this document. However, should any fee under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:038US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 5, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/671,340	09/25/2003	1614	450	GOUD:038US	6	19	1

CONFIRMATION NO. 4251

UPDATED FILING RECEIPT



OC000000012164342

Michael R. Krawzsenek
Fulbright & Jaworski L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701

Date Mailed: 03/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Denis Gravel, St-Lambert, CANADA;
Krishna Perl, St-Laurent, CANADA;
Thierry Abribat, Montreal, CANADA;
Abdelkrim Habi, Dollard des Ormeaux, CANADA;

Assignment For Published Patent Application

~~THERATECHNOLOGIES INC.~~ THERATECHNOLOGIES INC.

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/413,171 09/25/2002

Foreign Applications

If Required, Foreign Filing License Granted: 01/12/2004

Projected Publication Date: 07/01/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

27 2004
GOUD:038US

SLB

Title

Modified GLP-1 peptides with increased biological potency

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

ASSIGNMENT OF INVENTION

UNIVERSAL

WHEREAS, the invention described in U.S. Application No. 10/871,340 "MODIFIED GLP-1 PEPTIDES WITH INCREASED BIOLOGICAL POTENCY", filed on September 25, 2003, which claimed the priority of U.S. Application No. 60/413,171, filed on September 25, 2002, or a part of said invention, was assigned on September 25, 2002 (hereinafter referred as the "past assignment") by (1) DENIS GRAVEL, (2) KRISHNA PERI, (3) THIERRY ABRIBAT, (4) ABDELKRIM HABI, whose full addresses are (1) 207 des Pyrénées, St-Lambert, Québec, Canada J4S 1L3, (2) 3130 boul. Toupin, St-Laurent, Québec, Canada H4K 1Y8, (3) 4659 Hutchison, Montréal, Québec, Canada H2V 4A2, (4) 4890 Arthur, Dollard des Ormeaux, Québec, Canada H9G 2M8 (hereinafter referred to as the "assignors") to THERATECHNOLOGIES INC., whose full address is 2310 boulevard Alfred-Nobel, Saint-Laurent, Québec, Canada H4S 2A4 (hereinafter referred to as the "assignee"); and

WHEREAS the assignor and the assignee are desirous of confirming this past assignment;

WHEREAS the assignor is desirous of assigning and the assignee is desirous of obtaining any part of said invention not previously assigned.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other valuable consideration, the receipt of which is hereby acknowledged, the assignors have and by these presents do hereby sell, assign and transfer unto said assignee, its successors and assigns, the entire right, title and interest in and to said part of said invention not previously assigned as described in the aforesaid application, in any form or embodiment thereof, and in and to the aforesaid application; and in and to any applications based thereon filed in any foreign country, including the right to file said foreign applications under the provisions of the Patent Cooperation Treaty and under the Paris Convention; also the entire right, title and interest in and to any and all patents, reissues or extensions thereof to be obtained in this or any foreign country upon said invention or inventions and any divisional, continuation, continuation-in-part, substitute application(s) or supplementary disclosure(s) which may be filed upon said invention or inventions, in any country; and the assignors hereby authorize and request the issuing authority to issue any and all patents on said application or applications to said assignee.

The assignors further agree without any payment by said assignee other than expenses incurred by the undersigned, to communicate to said assignee, its representatives or agents, any facts relating to said invention or inventions, including evidence for interference purposes or for other proceedings, whenever requested; testify in any interference, litigation or other proceedings, whenever requested; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective, and likewise make these provisions binding upon the assignors heirs, legal representatives, administrators and assigns.


Les soussignés désirent que la présente cession soit en anglais. The undersigned requests that the present assignment be in English.

IN WITNESS WHEREOF, the assignors and assignee have hereunto set their hands and seal.


WITNESS

DATE

ASSIGNOR



JAN 16, 2004


DENIS GRAVEL

WITNESS

DATE

ASSIGNOR




January 5, 2004


KRISHNA PERI

WITNESS

DATE

ASSIGNOR




January 6, 2004


THIERRY ABRIBAT

WITNESS

DATE

ASSIGNOR




January 6, 2004


ABDELKRIM HABI


WITNESS

DATE

ASSIGNEE



January 20, 2004


Name and title of authorised
representative
THERATECHNOLOGIES INC.

Effective on September 25, 2003.